Neuromodulation Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application (Chronic Pain Management, Failed back syndrome, Epilepsy, Tremor, Incontinence, Depression, Dystonia, Gastroparesis, Parkinsons disease, Obsessive-Compulsive Disorder, Migraine) and Biomaterial (Metallic, Polymeric, Ceramic) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022
- ALL2344418
- 127 Pages
- August 2016
- Healthcare
The global neuromodulation market size is expected to reach $11,717 million by 2022, registering a CAGR of 13.1% from 2016 to 2022. The global neuromodulation devices market is estimated to reach $11,717 million by 2022.
Neurological disorders such as epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous system. Bacterial, viral, and fungal infections can also cause neurological disorders. To manage such disorders, neuromodulation is used, wherein small electrodes generate electrical most precise stimulation with the help of pulse generators to supplement neurological activities in effected people. The electrodes are generally placed directly in the brain or peripheral nerves or spinal cord whereas pulse generators are implanted within the skin. The key drivers for the growth of neuromodulation market include rise in geriatric population, their vulnerability for neurological disorders, increase in incidence of neurological diseases, such as Alzheimer’s and Parkinson’s diseases, and the increase in awareness regarding the safety and efficacy of neurostimulator devices. However, restrains, such as lack of trained healthcare professionals and stringent approval policies, are expected to hinder the market.
The report analyzes the neuromodulation market based on product type, namely, internal and external neuromodulators. Internal neuromodulators are further segmented into deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, spinal cord stimulation, and other neurostimulators, whereas external neuromodulators are classified into transcutaneous electrical nerve stimulation and repetitive transcranial magnetic stimulation. The market is also segmented based on application, material, and geography. The report includes the revenue generated from the sales of the previously mentioned segments of neuromodulator devices. Spinal cord stimulation is the dominating segment whereas repetitive transcranial magnetic stimulation is the fastest growing segment among various neuromodulation technologies. Chronic pain management is the largest application segment and migraine is the fastest growing segment owing to the high incidence rate.The spinal cord stimulation has huge potential to treat widespread chronic back pain. Around 20% of adult Americans experience chronic pain. Recently, USFDA and similar regulatory agencies have approved many products of the SCS technology, for instance Senza SCS System by Nevro Corporation and Proclaim Elite SCS by St. Jude Medical. The use of technology is expanding to new indications such as failed-back surgery syndrome, refractory angina pectoris, peripheral vascular disease, and complex regional pain syndrome. Deep Brain Stimulation (DBS) market is projected to exhibit significant growth due to high adoption rate in developed economies for neurological disorders, such as Parkinson’s disease, which have no known cure. The use of DBS is expanding to new indications such as severe obsessive-compulsive disorder, treatment-resistant depression, Alzheimer's type dementia, and movement disorders.
Tremor is one of the major applications of neuromodulation devices. Tremor is a nerve disorder characterized by uncontrollable shaking or tremors in different parts of the body such as hands, arms, head, larynx (voice box), tongue, and chin. Tremor affects several million people above the age of 40 years. It is majorly caused due to genetic mutations. Tremor impairs routine activities, such as eating, drinking, and writing of patients. Number of implantable deep brain stimulators is now available for the management of tremors. For instance, Medtronic’s deep brain neurostimulators are implanted surgically within the thalamus, which is the brain’s communication center. The lead is connected to an implanted pulse generator by an extension wire running beneath the skin. The electrical stimulation can be noninvasively adjusted to block signals that cause disabling motor symptoms of essential tremor. Increasing prevalence of this disorder, technological improvement in neurostimulator devices, and increasing FDA approvals for neurostimulators are expected to drive the market.
North America is the most attractive market in the global neuromodulation industry and is expected to be the first preference for new entrants due to the increasing end-use in the region. Asia-Pacific is the fastest growing market; hence the established players are focusing on the region.
Government and private initiatives to increase awareness regarding mental health and increase in incidence of neurological disorders drive the market growth in Asia Pacifc. Japan has the highest revenue share in the region, followed by China. India is projected to witness rapid growth in future due to growing awareness regarding mental disorders and increasing expenditure in the healthcare sector. In Japan, Pharmaceutical and Medical Devices Agency has approved numerous neurostimulators for pain management since 2010 such as Eon Mini and Genesis spinal cord stimulation (SCS) system by St. Jude and Precision Spectra by Boston Scientific. Increase in approval rate of neurostimulators by the Pharmaceuticals and Medical Devices Agency (PMDA) has fueled their adoption in the Japanese market.
The report also provides comprehensive analysis of the key players operating in the global neuromodulation market such as Medtronic plc, St. Jude Medical, Inc., LivaNova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, BioControl Medical, Bioness Inc., EnteroMedics Inc, Nevro Corporation and NeuroPace Inc. The report presents competitive market study by analyzing market shares and position of major players, recent strategic moves and detailed profiles of these players.
NEUROMODULATION MARKET KEY BENEFITS
The study provides an in-depth analysis of the global neuromodulation market with current trends and future estimations to elucidate the imminent investment pockets.
- The report provides a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- The report provides actual historical figures for 2014 and 2015 and provides Y-o-Y forecasts for 2016 to 2022, considering 2015 as base year.
- Extensive analysis by product helps in understanding the various types of devices used for the treatment of neurological diseases and other related conditions.
- Competitive intelligence highlights the business practices followed by leading players across various regions.
- SWOT analysis studies the internal environment of the leading companies for strategy formulation.
NEUROMODULATION MARKET SEGMENTS
The global neuromodulation market is segmented based on technology, applications, material and geography.
By Technology
- Internal neuromodulation
- Deep Brain Stimulation
- Sacral Nerve Stimulation
- Vagus Nerve Stimulation
- Spinal Cord Stimulation
- Other Neuromodulation Technologies
- External neuromodulation
- Transcutaneous Electrical Nerve Stimulation
- Transcranial Magnetic Stimulation
By Application
- Chronic Pain Management
- Failed back syndrome
- Epilepsy
- Tremor
- Urinary and Fecal Incontinence
- Depression
- Dystonia
- Gastroparesis
- Parkinson's disease
- Obsessive-Compulsive Disorder
- Migraine
- Other Applications
By Biomaterial
- Metallic Biomaterials
- Polymeric Biomaterials
- Ceramic Biomaterials
By Region
- North America
- U.S.
- Canada
- Mexic
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Malaysia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Israel
- South Africa
- Saudi Arabia
- Rest of LAMEA
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Research methodology
1.3.1 Secondary research
1.3.2 Primary research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Intensity of rivalry
3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Ageing population and increasing incidence of neurological diseases
3.5.1.2 Rise in the number of migraine and epilepsy patients and increase of neurostimulators in the treatment of depression and sleep apnea
3.5.1.3 Increasing focus of leading companies in the neurostimulation segment
3.5.1.4 New device approvals and increased clinical evidence of effectiveness
3.5.2 Restraints
3.5.2.1 Lack of skilled professionals
3.5.2.2 High cost and lack of reimbursement
3.5.3 Opportunities
3.5.3.1 Rising healthcare expenditure in developing countries
3.5.3.2 Use of neurostimulators for new indications
3.5.3.3 Rising patient awareness about nuerostimulators
CHAPTER 4 WORLD NEUROMODULATION MARKET, BY TECHNOLOGY
4.1 Overview
4.1.1 Market size and forecast
4.2 Internal neuromodulation
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Deep brain stimulation
4.2.4.1 Market size and forecast
4.2.5 Sacral nerve stimulation
4.2.5.1 Market size and forecast
4.2.6 Spinal cord stimulation
4.2.6.1 Market size and forecast
4.2.7 Vagus nerve stimulation
4.2.7.1 Market size and forecast
4.2.8 Other neuromodulation
4.2.8.1 Market size and forecast
4.3 External Neuromodulation
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Transcutaneous electrical nerve stimulation
4.3.4.1 Market size and forecast
4.3.5 Transcranial magnetic stimulation
4.3.5.1 Market size and forecast
CHAPTER 5 WORLD NEUROMODULATION MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Failed back syndrome
5.2.1 Market size and forecast
5.3 Chronic pain
5.3.1 Market size and forecast
5.4 Epilepsy
5.4.1 Market size and forecast
5.5 Essential tremor
5.5.1 Market size and forecast
5.6 Urinary and fecal incontinence
5.6.1 Market size and forecast
5.7 Depression
5.7.1 Market size and forecast
5.8 Dystonia
5.8.1 Market size and forecast
5.9 Gastroparesis
5.9.1 Market size and forecast
5.10 Parkinson's disease
5.10.1 Market size and forecast
5.11 Migraine
5.11.1 Market size and forecast
5.12 Obsessive-compulsive disorder
5.12.1 Market size and forecast
5.13 Other applications
5.13.1 Market size and forecast
CHAPTER 6 WORLD NEUROMODULATION MARKET, BY BIOMATERIAL
6.1 Overview
6.1.1 Market size and forecast
6.2 Ceramics biomaterials
6.2.1 Market size and forecast
6.3 Metallic biomaterials
6.3.1 Market size and forecast
6.4 Polymeric biomaterials
6.4.1 Market size and forecast
CHAPTER 7 WORLD NEUROMODULATION MARKET, BY GEOGRAPHY
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.2.3.1 U.S. market size and forecast
7.2.3.2 Canada market size and forecast
7.2.3.3 Mexico market size and forecast
7.3 Europe
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.3.3.1 Germany market size and forecast
7.3.3.2 France market size and forecast
7.3.3.3 U.K. market size and forecast
7.3.3.4 Italy market size and forecast
7.3.3.5 Spain market size and forecast
7.3.3.6 Rest of europe market size and forecast
7.4 Asia-Pacific
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.4.3.1 Japan market size and forecast
7.4.3.2 China market size and forecast
7.4.3.3 India market size and forecast
7.4.3.4 South Korea market size and forecast
7.4.3.5 Malaysia market size and forecast
7.4.3.6 Rest of Asia-Pacific market size and forecast
7.5 LAMEA
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
7.5.3.1 Brazil market size and forecast
7.5.3.2 Israel market size and forecast
7.5.3.3 Saudi Arabia market size and forecast
7.5.3.4 South Africa market size and forecast
7.5.3.5 Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 Aleva Neurotherapeutics SA
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Key strategic moves & developments
8.2 BioControl Medical
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Key strategic moves & developments
8.3 Bioness Inc.
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Key strategic moves & developments
8.4 Boston Scientific Corporation
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Business performance
8.4.5 Key strategic moves & developments
8.5 EnteroMedics Inc.
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Business performance
8.5.5 Key strategic moves & developments
8.6 LivaNova PLC
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Business performance
8.6.5 Key strategic moves & developments
8.7 Medtronic plc
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Business performance
8.7.5 Key strategic moves & developments
8.8 NeuroPace, Inc.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Key strategic moves & developments
8.9 Nevro Corporation
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Business performance
8.9.5 Key strategic moves & developments
8.10 St. Jude Medical, Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Business performance
8.10.5 Key strategic moves & developments
List of Figures
FIG. 1 TOP INVESTMENT POCKETS IN WORLD NEUROMODULATION MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIG. 3 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 4 PORTERS FIVE FORCES ANALYSIS
FIG. 5 MARKET SHARE ANALYSIS, 2015
FIG. 6 U.S. NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 7 CANADA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 8 MEXICO NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 9 GERMANY NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 10 FRANCE NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 11 U.K. NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 12 ITALY NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 13 SPAIN NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 14 REST OF EUROPE NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 15 JAPAN NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 16 CHINA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 17 INDIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 18 SOUTH KOREA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 19 MALAYSIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 20 REST OF ASIA-PACIFIC NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 21 BRAZIL NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 22 ISRAEL NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 23 SAUDI ARABIA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 24 SOUTH AFRICA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 25 REST OF LAMEA NEUROMODULATION MARKET, 2014-2022 ($MILLION)
FIG. 26 BOSTON SCIENTIFIC: REVENUE, 20132015 ($MILLION)
FIG. 27 BOSTON SCIENTIFIC: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 28 BOSTON SCIENTIFIC: REVENUE, BY SUB SEGMENT, 2015 (%)
FIG. 29 BOSTON SCIENTIFIC: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 30 LIVANOVA: REVENUE, 20132015 ($MILLION)
FIG. 31 LIVANOVA: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 32 LIVANOVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 33 LIVANOVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 34 MEDTRONIC: REVENUE, 20142016 ($MILLION)
FIG. 35 MEDTRONIC: REVENUE, BY SEGMENT, 2016 (%)
FIG. 36 MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUBSEGMENT, 2016 (%)
FIG. 37 MEDTRONIC: REVENUE, BY GEOGRAPHY, 2016 (%)
FIG. 38 NEVRO: REVENUE, 20132015 ($MILLION)
FIG. 39 NEVRO: REVENUE BY GEOGRAPHY, 2015 (%)
FIG. 40 ST. JUDE MEDICAL: REVENUE, 20132015 ($MILLION)
FIG. 41 ST. JUDE MEDICAL: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 42 ST. JUDE MEDICAL: REVENUE, BY GEOGRAPHY, 2015 (%)
List of Tables
TABLE 1 WORLD NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 2 INTERNAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 3 EXTERNAL NEUROMODULATION MARKET, BY TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 4 WORLD NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 5 NEUROMODULATION MARKET FOR FAILED BACK SYNDROME, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6 NEUROMODULATION MARKET FOR CHRONIC PAIN, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 NEUROMODULATION MARKET FOR EPILEPSY, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 NEUROMODULATION MARKET FOR ESSENTIAL TREMOR, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 NEUROMODULATION MARKET FOR URINARY AND FECAL INCONTINENCE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10 NEUROMODULATION MARKET FOR DEPRESSION, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 NEUROMODULATION MARKET FOR DYSTONIA, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 NEUROMODULATION MARKET FOR GASTROPARESIS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 NEUROMODULATION MARKET FOR PARKINSONS DISEASE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 14 NEUROMODULATION MARKET FOR MIGRAINE, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 NEUROMODULATION MARKET FOR OBSESSIVE-COMPULSIVE DISORDER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 NEUROMODULATION MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 WORLD NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 18 NEUROMODULATION MARKET FOR CERAMIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 NEUROMODULATION MARKET FOR METALLIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 NEUROMODULATION MARKET FOR POLYMERIC BIOMATERIALS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 21 NEUROMODULATION MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22 NORTH AMERICA NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 23 NORTH AMERICA NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 24 NORTH AMERICA NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 25 EUROPE NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 26 EUROPE NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 27 EUROPE NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 28 ASIA-PACIFIC NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29 ASIA-PACIFIC NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 30 ASIA-PACIFIC NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 31 LAMEA NEUROMODULATION MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 32 LAMEA NEUROMODULATION MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 33 LAMEA NEUROMODULATION MARKET, BY BIOMATERIAL, 2014-2022 ($MILLION)
TABLE 34 ALEVA: COMPANY SNAPSHOT
TABLE 35 ALEVA: PRODUCT CATEGORIES
TABLE 36 BIOCONTROL MEDICAL: COMPANY SNAPSHOT
TABLE 37 BIOCONTRL MEDICAL: PRODUCT CATEGORIES
TABLE 38 BIONESS: COMPANY SNAPSHOT
TABLE 39 BIONESS: PRODUCT CATEGORIES
TABLE 40 BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 41 BOSTON SCIENTIFIC: PRODUCT CATEGORIES
TABLE 42 ENTEROMEDICSINC: COMPANY SNAPSHOT
TABLE 43 ENTEROMEDICSINC: PRODUCT CATEGORIES
TABLE 44 LIVANOVA: COMPANY SNAPSHOT
TABLE 45 LIVANOVA: PRODUCT CATEGORIES
TABLE 46 MEDTRONIC: COMPANY SNAPSHOT
TABLE 47 MEDTRONIC: OPERATING SEGMENTS
TABLE 48 NEUROPACE: COMPANY SNAPSHOT
TABLE 49 NEVRO: COMPANY SNAPSHOT
TABLE 50 NEVRO: PRODUCT CATEGORIES
TABLE 51 ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 52 ST. JUDE MEDICAL: PRODUCT CATEGORIES
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
